Switch theme
Sign up to access all valuation multiples
Transgene SA is a biotechnology company that designs and develops targeted immunotherapy products for cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The company's portfolio of products in clinical development includes TG4050, an individualized therapeutic vaccine based on the myvac platform, TG4001, a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Geographically, the majority of its operations are located in France.
1979
165
LTM Revenue $23.2M
LTM EBITDA -$22.6M
$82.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Transgene has a last 12-month revenue (LTM) of $23.2M and a last 12-month EBITDA of -$22.6M.
In the most recent fiscal year, Transgene achieved revenue of $0.3M and an EBITDA of -$34.8M.
Transgene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Transgene valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $23.2M | XXX | $0.3M | XXX | XXX | XXX |
| Gross Profit | $23.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$22.6M | XXX | -$34.8M | XXX | XXX | XXX |
| EBITDA Margin | -98% | XXX | -10101% | XXX | XXX | XXX |
| EBIT | -$19.4M | XXX | -$40.1M | XXX | XXX | XXX |
| EBIT Margin | -84% | XXX | -11624% | XXX | XXX | XXX |
| Net Profit | -$24.7M | XXX | -$38.2M | XXX | XXX | XXX |
| Net Margin | -107% | XXX | -11065% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Transgene's stock price is EUR 1 (or $1).
Transgene has current market cap of EUR 90.0M (or $101M), and EV of EUR 73.3M (or $82.3M).
See Transgene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $82.3M | $101M | XXX | XXX | XXX | XXX | $-0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Transgene has market cap of $101M and EV of $82.3M.
Transgene's trades at 238.8x EV/Revenue multiple, and -2.4x EV/EBITDA.
Equity research analysts estimate Transgene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Transgene has a P/E ratio of -4.1x.
See valuation multiples for Transgene and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $101M | XXX | $101M | XXX | XXX | XXX |
| EV (current) | $82.3M | XXX | $82.3M | XXX | XXX | XXX |
| EV/Revenue | 3.6x | XXX | 238.8x | XXX | XXX | XXX |
| EV/EBITDA | -3.6x | XXX | -2.4x | XXX | XXX | XXX |
| EV/EBIT | -4.3x | XXX | -2.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.1x | XXX | -2.6x | XXX | XXX | XXX |
| EV/FCF | -2.9x | XXX | -2.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTransgene's last 12 month revenue growth is 34%
Transgene's revenue per employee in the last FY averaged $2K, while opex per employee averaged $0.2M for the same period.
Transgene's rule of 40 is -1705% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Transgene's rule of X is -13% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Transgene and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 34% | XXX | 547% | XXX | XXX | XXX |
| EBITDA Margin | -98% | XXX | -10101% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1705% | XXX | -10067% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -13% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11165% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 11724% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Transgene acquired XXX companies to date.
Last acquisition by Transgene was XXXXXXXX, XXXXX XXXXX XXXXXX . Transgene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Transgene founded? | Transgene was founded in 1979. |
| Where is Transgene headquartered? | Transgene is headquartered in France. |
| How many employees does Transgene have? | As of today, Transgene has 165 employees. |
| Who is the CEO of Transgene? | Transgene's CEO is Dr. Alessandro Riva, M.D.. |
| Is Transgene publicy listed? | Yes, Transgene is a public company listed on PAR. |
| What is the stock symbol of Transgene? | Transgene trades under TNG ticker. |
| When did Transgene go public? | Transgene went public in 1998. |
| Who are competitors of Transgene? | Similar companies to Transgene include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Transgene? | Transgene's current market cap is $101M |
| What is the current revenue of Transgene? | Transgene's last 12 months revenue is $23.2M. |
| What is the current revenue growth of Transgene? | Transgene revenue growth (NTM/LTM) is 34%. |
| What is the current EV/Revenue multiple of Transgene? | Current revenue multiple of Transgene is 3.6x. |
| Is Transgene profitable? | Yes, Transgene is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Transgene? | Transgene's last 12 months EBITDA is -$22.6M. |
| What is Transgene's EBITDA margin? | Transgene's last 12 months EBITDA margin is -98%. |
| What is the current EV/EBITDA multiple of Transgene? | Current EBITDA multiple of Transgene is -3.6x. |
| What is the current FCF of Transgene? | Transgene's last 12 months FCF is -$28.7M. |
| What is Transgene's FCF margin? | Transgene's last 12 months FCF margin is -124%. |
| What is the current EV/FCF multiple of Transgene? | Current FCF multiple of Transgene is -2.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
